Company
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. has 1 drug tracked on RxWires: 1 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Furmonertinib | Phase 1 | Non-Small Cell Lung Cancer (NSCLC) |
Latest
No recent events.
Follow ArriVent BioPharma, Inc. on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.